IDEA EV06

Phase:
I
Status:
Scheduled
Strategies:
DNA, Protein
Candidates:
DNA-HIV-PT123, AIDSVAX B/E
Countries:
Uganda
Volunteers:
72
Partners:
IAVI; EuroVacc Foundation
 

A phase I double blind placebo-controlled clinical trial to evaluate the safety and immunogenicity of the combination of DNA-HIV-PT123 and AIDSVAX ® B/E in HIV-1-uninfected adult participants with or without underlying Schistosoma mansoni (S. mansoni) infection.

N004 (HIVCORE 004)

Phase:
I/IIA
Status:
Ongoing
Strategies:
DNA, Viral Vector - Pox, Viral Vector-Adeno
Candidates:
Ad35-GRIN, MVA.HIVconsv, pSG2.HIVconsvDNA
Countries:
Kenya
Volunteers:
72
Partners:
IAVI; University of Oxford; European and Developing Countries Clinical Trials Partnership (EDCTP); Karolinska Institutet; University of Nairobi Ichor Medical Systems Incorporated
 
A Phase I/IIa Clinical Trial of HIV-1 Vaccines pSG2.HIVconsv DNA, MVA.HIVconsv and Ad35-GRIN in Combined Regimens in Healthy HIV-1/2-negative Adults in Nairobi
 
The study is part of a long-term aim to develop an effective HIV-1 vaccine and will evaluate safety and immunogenicity of vaccines focusing T cell responses on  the conserved region of the HIV-1 proteome. The vaccines used are pSG2.HIVconsv DNA (D), MVA.HIVconsv (M) and Ad35-GRIN (A), delivered in regimens AM, DDDAM and DeDeDeAM, where e indicates electroporation. ClinicalTrials.gov Identifier: NCT02099994

PAVE 100

Phase:
IIb
Status:
Withdrawn
Strategies:
DNA, Viral Vector - Adeno
Candidates:
VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP
Countries:
USA
Volunteers:
0

A test-of-concept clinical trial to evaluate the efficacy, safety, and immunogenicity of a multiclade HIV-1 DNA plasmid vaccine, VRC-HIVDNA016-00-VP, followed by a multiclade recombinant adenoviral vector vaccine, VRC-HIVADV014-00-VP.

X001

Phase:
I
Status:
Ongoing
Strategies:
Protein
Candidates:
CN54gp140 mixed with GLA-AF
Countries:
United Kingdom
Volunteers:
12
Partners:
IAVI; Imperial College; Wellcome Trust; National Institute for Health Research, United Kingdom.
 

A Phase 1 Open-Labelled Trial to Evaluate the Safety and Immunogenicity of CN54gp140 in HIV-Uninfected, Healthy Volunteers.
ClinicalTrials.gov Identifier: NCT01966900

IAVI V002

Phase:
II
Status:
Withdrawn
Strategies:
DNA, Viral Vector - Adeno
Candidates:
VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP
Countries:
Kenya;Rwanda;Uganda;Zambia
Volunteers:
0

A randomized, placebo-controlled, double-blind trial to evaluate the safety and immunogenicity of a multiclade HIV-1 DNA plasmid vaccine followed by recombinant, multiclade HIV-1 adenoviral vector vaccine.